Clinical Trial Detail

NCT ID NCT02807844
Title Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

melanoma

endometrial carcinoma

pancreatic carcinoma

triple-receptor negative breast cancer

Therapies

MCS110 + Spartalizumab

Age Groups: adult senior

No variant requirements are available.